Lidocaine vaginal - Enhance Pharmaceuticals

Drug Profile

Lidocaine vaginal - Enhance Pharmaceuticals

Latest Information Update: 24 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enhance Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Cell membrane permeability inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaesthesia

Most Recent Events

  • 24 Apr 2007 Discontinued - Preclinical for Anaesthesia in USA (Vaginal)
  • 17 Jun 2002 Enhance Pharmaceuticals has been acquired by Barr Laboratories
  • 28 Mar 2002 Barr Laboratories expects to acquire Enhance, subject to conditions, by June 30, 2002
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top